1. Home
  2. STRS vs ELTX Comparison

STRS vs ELTX Comparison

Compare STRS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratus Properties Inc.

STRS

Stratus Properties Inc.

HOLD

Current Price

$19.70

Market Cap

220.4M

Sector

Real Estate

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.83

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRS
ELTX
Founded
1992
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.4M
185.4M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
STRS
ELTX
Price
$19.70
$2.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
102.9K
877.0K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
512.50
39.29
EPS
0.82
N/A
Revenue
$29,914,000.00
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.53
$2.66
52 Week High
$32.93
$16.00

Technical Indicators

Market Signals
Indicator
STRS
ELTX
Relative Strength Index (RSI) 16.48 34.75
Support Level $18.51 $2.72
Resistance Level $20.57 $5.38
Average True Range (ATR) 0.74 0.22
MACD 0.01 0.21
Stochastic Oscillator 24.02 20.31

Price Performance

Historical Comparison
STRS
ELTX

About STRS Stratus Properties Inc.

Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: